WCLC 2025 - Posters & ePosters-P1.17.68 Real-World Validation of Other Disease Morbidity After Lung Cancer Surgery Using a Japanese Database in Reference to JCOG0802/WJOG4607L

P1.17.68 Real-World Validation of Other Disease Morbidity After Lung Cancer Surgery Using a Japanese Database in Reference to JCOG0802/WJOG4607L

Back to course

Pdf Summary

This study validated real-world data on non-cancer morbidity after lung cancer surgery using a Japanese health insurance database, focusing on outcomes after segmentectomy versus lobectomy. Building on the JCOG0802/WJOG4607L phase III trial—which showed segmentectomy superior to lobectomy in overall survival (OS) largely due to fewer deaths from other diseases—the researchers analyzed hospitalization rates for diseases like pneumonia, cerebral infarction, and heart conditions in 6,328 lung cancer surgery patients (3,349 lobectomy, 744 segmentectomy) aged mostly 20–50.<br /><br />Using medical claims covering hospitalizations, outpatient visits, and prescriptions, they found significantly higher rates of post-surgery hospitalizations for pneumonia (7.4% vs. 4.6%), congestive heart failure, and cerebral infarction (1.9% vs. 0.5%) in the lobectomy group compared to segmentectomy. These hospitalizations were associated with significantly worse OS. The higher pneumonia rate after lobectomy likely relates to greater respiratory function decline post-surgery, while increased cerebral infarction may be linked to complications such as pulmonary vein stump thrombosis and atrial fibrillation, more common after lobectomy.<br /><br />Despite limitations—including lack of cancer staging and adjuvant therapy data and unclear surgical indication criteria—the study supports that segmentectomy reduces non-cancer morbidity and related hospitalizations compared to lobectomy. The findings imply that, particularly in older populations, non-cancer hospitalizations after lobectomy may contribute significantly to reduced survival.<br /><br />In conclusion, this real-world evidence corroborates clinical trial results by demonstrating that segmentectomy is associated with lower rates of serious postoperative morbidities and better overall survival than lobectomy in lung cancer surgery patients.

Asset Subtitle

Taihei Takeuchi

Meta Tag

Speaker Taihei Takeuchi

Topic Global Health, Health Services, and Health Economics

Keywords

lung cancer surgery

segmentectomy

lobectomy

non-cancer morbidity

Japanese health insurance database

postoperative pneumonia

cerebral infarction

congestive heart failure

overall survival

pulmonary vein stump thrombosis